Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05292417 |
TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC | 阶段
第二阶段
|
Date Added 2022-03-23 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, GM-CSF, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT04687631 |
Title最初无法切除肝转移灶的 RAS/BRAF 野生型结直肠癌患者的转换疗法 | 阶段
第三阶段
|
Date Added 2020-12-29 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID LUMINESCENCE |
TitleIpilimumab, Maraviroc and Nivolumab (LUMINESCENCE) | 阶段
第 1 阶段
|
Date Added 2019-01-25 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy |
标签
MSS/ MMRp
|
| NCT ID NCT04866862 |
TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-04-30 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Combination of Fruquintinib and Camrelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT03835949 |
TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer | 阶段
第 1 阶段
|
Date Added 2019-02-11 |
地点
Alabama, United States
Arizona, United States California, United States Texas, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Atezolizumab, TJ004309 |
标签
MSS/ MMRp
|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2020-06-16 |
地点
Missouri, United States
Texas, United States Utah, United States Virginia, United States 法国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
AN0025, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT03239145 |
TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | 阶段
第 1 阶段
|
Date Added 2017-08-03 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Trebananib |
标签
MSS/ MMRp
|
| NCT ID NCT03494946 |
Title结直肠癌患者肝移植与化疗的比较 | 阶段
不适用
|
Date Added 2018-04-11 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
化疗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03911557 |
TitleDurvalumab和Tremelimumab联合治疗体细胞高突变复发性实体瘤 | 阶段
第二阶段
|
Date Added 2019-04-11 |
地点
Kentucky, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Durvalumab和Tremelimumab |
标签
MSS/ MMRp
|
| NCT ID NCT03030378 |
Title治疗实体瘤患者的 Pembrolizumab 和重组白细胞介素-12 | 阶段
第 1 阶段
|
Date Added 2017-01-25 |
地点
California, United States
Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Edodekin alfa, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
